Cannabinoid receptors modulate LPS-induced increase of class-II transactivator expression levels in a microglial cell line

References

• An D, Peigneur S, Hendrickx LA, et al. Targeting cannabinoid receptors: Current status and prospects of natural products. Int J Mol Sci. 2020;21(14):5064.
   Web of Science ®Google Scholar
• Walsh KB, Andersen HK. Molecular pharmacology of synthetic cannabinoids: Delineating cb1 receptor-mediated cell signaling. Int J Mol Sci. 2020;21(17):6115.
   Web of Science ®Google Scholar
• Shahbazi F, Grandi V, Banerjee A, et al. Cannabinoids and cannabinoid receptors: the story so far. iScience. 2020;23(7):101301.
   PubMed Web of Science ®Google Scholar
• Nazıroğlu M, Taner AN, Balbay E, et al. Inhibitions of anandamide transport and FAAH synthesis decrease apoptosis and oxidative stress through inhibition of TRPV1 channel in an in vitro seizure model. Mol Cell Biochem. 2019;453(1-2):143–155.
   PubMed Web of Science ®Google Scholar
• Nazıroglu M. TRPV1 Channel: a potential drug target for treating epilepsy. CN. 2015;13(2):239–247.
   Google Scholar
• Kendall DA, Yudowski GA. Cannabinoid receptors in the central nervous system: their signaling and roles in disease. Front Cell Neurosci. 2017;10:294.
   PubMed Web of Science ®Google Scholar
• Wu J. Cannabis, cannabinoid receptors, and endocannabinoid system: yesterday, today, and tomorrow. Acta Pharmacol Sin. 2019;40(3):297–299.
   PubMed Web of Science ®Google Scholar
• Zou S, Kumar U. Cannabinoid receptors and the endocannabinoid system: signaling and function in the central nervous system. Int J Mol Sci. 2018;19(3):833.
   PubMed Web of Science ®Google Scholar
• Murphy T, Le Foll B. Targeting the endocannabinoid CB1 receptor to treat body weight disorders: a preclinical and clinical review of the therapeutic potential of past and present CB1 drugs. Biomolecules. 2020;10(6):855.
   Web of Science ®Google Scholar
• Svensson M, Chen P, Hammarfjord O. Dendritic cell regulation by cannabinoid-based drugs. Pharmaceuticals (Basel)). 2010;3(8):2733–2750.
   PubMedGoogle Scholar
• Klein TW. Cannabinoid-based drugs as anti-inflammatory therapeutics. Nat Rev Immunol. 2005;5(5):400–411.
   PubMed Web of Science ®Google Scholar
• Walter L, Franklin A, Witting A, et al. Nonpsychotropic cannabinoid receptors regulate microglial cell migration. J Neurosci. 2003;23(4):1398–1405.
   PubMed Web of Science ®Google Scholar
• Lu HC, MacKie K. An introduction to the endogenous cannabinoid system. Biol Psychiatry. 2016;79(7):516–525.
   PubMed Web of Science ®Google Scholar
• Wacnik PW, Luhr KM, Hill RH, et al. Cannabinoids affect dendritic cell (DC) potassium channel function and modulate DC T cell stimulatory capacity. J Immunol. 2008;181(5):3057–3066.
   PubMed Web of Science ®Google Scholar
• Chung YC, Bok E, Huh SH, et al. Cannabinoid receptor Type 1 protects nigrostriatal dopaminergic neurons against MPTP neurotoxicity by inhibiting microglial activation. J Immunol. 2011;187(12):6508–6517.
   PubMed Web of Science ®Google Scholar
• Racz I, Nadal X, Alferink J, et al. Interferon-gamma is a critical modulator of CB(2) cannabinoid receptor signaling during neuropathic pain . J Neurosci. 2008;28(46):12136–12145.
   PubMed Web of Science ®Google Scholar
• Gongora C, Hose S, O'Brien TP, et al. Downregulation of class II transactivator (CIITA) expression by synthetic cannabinoid CP55,940. Immunol Lett. 2004;91(1):11–16.
   PubMed Web of Science ®Google Scholar
• Oz B, Yildirim A, Yolbas S, et al. Resveratrol inhibits Src tyrosine kinase, STAT3, and Wnt signaling pathway in collagen induced arthritis model. Biofactors. 2019;45(1):69–74.
   PubMed Web of Science ®Google Scholar
• Ativie F, Komorowska JA, Beins E, et al. Cannabinoid 1 receptor signaling on hippocampal GABAergic neurons influences microglial activity. Front Mol Neurosci. 2018;11:295.
   PubMed Web of Science ®Google Scholar
• Sheppard O, Coleman MP, Durrant CS. Lipopolysaccharide-induced neuroinflammation induces presynaptic disruption through a direct action on brain tissue involving microglia-derived interleukin 1 beta. J Neuroinflammation. 2019;16(1):106.
   PubMedGoogle Scholar
• Lively S, Schlichter LC. Microglia responses to pro-inflammatory stimuli (LPS, IFNγ + TNFα) and reprogramming by resolving cytokines (IL-4, IL-10). Front Cell Neurosci. 2018;12:215.
   PubMed Web of Science ®Google Scholar
• Garretti F, Agalliu D, Arlehamn CSL, et al. Autoimmmunity in parkinson’s disease: the role of α:-synuclein-specific T cells. Front Immunol. 2019;10:303.
   PubMed Web of Science ®Google Scholar
• Klein TW, Cabral GA. Cannabinoid-induced immune suppression and modulation of antigen-presenting cells. J Neuroimmune Pharmacol. 2006;1(1):50–64.
   PubMed Web of Science ®Google Scholar
• Lu T, Newton C, Perkins I, et al. Cannabinoid treatment suppresses the T-helper cell-polarizing function of mouse dendritic cells stimulated with Legionella pneumophila infection. J Pharmacol Exp Ther. 2006;319(1):269–276.
   PubMed Web of Science ®Google Scholar
• Maestroni GJM. The endogenous cannabinoid 2-arachidonoyl glycerol as in vivo chemoattractant for dendritic cells and adjuvant for Th1 response to a soluble protein . Faseb J. 2004;18(15):1914–1916.
   PubMedGoogle Scholar
• Ribeiro A, Ferraz-de-Paula V, Pinheiro ML, et al. Anandamide prior to sensitization increases cell-mediated immunity in mice. Int Immunopharmacol. 2010;10(4):431–439.
   PubMed Web of Science ®Google Scholar
• Kogan NM, Schlesinger M, Priel E, et al. HU-331, a novel cannabinoid-based anticancer topoisomerase II inhibitor. Mol Cancer Ther. 2007;6(1):173–183.
   PubMed Web of Science ®Google Scholar
• Massa F, Marsicano G, Hermann H, et al. The endogenous cannabinoid system protects against colonic inflammation. J Clin Invest. 2004;113(8):1202–1209.
   PubMed Web of Science ®Google Scholar
• Jean-Gilles L, Braitch M, Latif ML, et al. Effects of pro-inflammatory cytokines on cannabinoid CB1 and CB2 receptors in immune cells. Acta Physiol (Oxf)). 2015;214(1):63–74.
   PubMed Web of Science ®Google Scholar
• Mullen KM, Rozycka M, Rus H, et al. Potassium channels Kv1.3 and Kv1.5 are expressed on blood-derived dendritic cells in the central nervous system. Ann Neurol. 2006;60(1):118–127.
   PubMed Web of Science ®Google Scholar
• Mackie K. Mechanisms of CB1 receptor signaling: endocannabinoid modulation of synaptic strength. Int J Obes. 2006;30(S1):S19–S23.
   Google Scholar
• Watkins AR. Cannabinoid interactions with ion channels and receptors. Channels (Austin)). 2019;13(1):162–167.
   PubMed Web of Science ®Google Scholar